AlphaTON, Cyncado present preclinical findings on A2B, A2A receptor antagonists

AlphaTON Capital (ATON) and its wholly owned oncology subsidiary Tarus Therapeutics, operating as Cyncado Therapeutics announced a poster presentation at the Society for Immunotherapy of Cancer Annual Meeting, taking place November 5 to 9, 2025, in National Harbor, Maryland. The poster reports preclinical findings from work conducted by investigators at the National Cancer Institute at NCI laboratories. In these studies, NCI researchers evaluated combinations of selective adenosine A2B antagonism and A2A antagonism with antigen-specific cancer vaccines. Experiments in three therapeutic cancer vaccine mouse models, conducted by investigators at the Vaccine Branch of the National Cancer Institute in Bethesda, Maryland, support the conclusion that strategies optimized to inhibit both adenosine A2B and A2A receptor mediated immune suppression can synergize with therapeutic tumor-specific vaccines to provide a robust antitumor immune response that should be translatable to humans. Synergy was observed in the TC1 lung cancer model using a triple combination of co-administered TT-4, a selective A2B receptor antagonist and TT-10, a selective A2A receptor antagonist, together with an E7 peptide therapeutic vaccine. This triple combination significantly suppressed tumor growth, improved survival, and elicited specific intratumoral CD8+ T-cell responses. Notably, several mice receiving this combination displayed complete tumor regression and resisted tumor rechallenge without the addition of checkpoint inhibitors. Therapeutic synergy was confirmed in two additional murine models: the CT26 colon cancer model using irradiated CT26 cells as a whole-cell vaccine and the poorly immunogenic B16F10 melanoma model administered a gp100 peptide based vaccine. “This collaboration with NCI investigators reflects a multi-year effort to define how co-administration of selective A2B and A2A receptor antagonists can amplify vaccine-driven immunity,” said Robert Kramer, CEO. “Dose escalation for TT-10 in patients with solid tumors is nearing completion, and we are preparing TT-4 for first-patient dosing as part of our planned mesothelioma trial, with the goal of prioritizing indications where these investigational drugs can have the greatest impact.”